Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyumjev vs Humalog for Exercise-Induced Hypoglycemia in T1D
NCT05262387Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of insulin lispro in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in Plasma Glucose (PG) From the Start to the End of Exercise. Started Feb 2022; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05262387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262387.